Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy

Myostatin, a negative regulator of skeletal muscle growth, is a therapeutic target in muscle‐wasting diseases. Domagrozumab, a humanized recombinant monoclonal antibody, binds myostatin and inhibits activity. Domagrozumab was investigated in a phase II trial (NCT02310763) as a potential treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojciechowski, Jessica, Purohit, Vivek S., Harnisch, Lutz O., Dua, Pinky, Tan, Beesan, Nicholas, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828399/
https://www.ncbi.nlm.nih.gov/pubmed/36104012
http://dx.doi.org/10.1002/cpt.2747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828399/
https://www.ncbi.nlm.nih.gov/pubmed/36104012
http://dx.doi.org/10.1002/cpt.2747

Ejemplares similares